



| | |
|--------------|--|
| To: | BHS Mental Health County Operated and Contracted Service Providers |
| From: | Behavioral Health Services – Quality Assurance (QA) Unit |
| Date: | Sept 12, 2023 |
| Title | Change to Informed Consent for Psychotropic Medication Requirements |

[California Senate Bill \(SB\) 184](#) updated and superseded state regulations (Cal. Code Regs. Tit. 9, § 852) that required mental health facilities to obtain patient signatures to demonstrate informed consent for antipsychotic medications delivered in specified community mental health settings. (Reference: [WIC § 5325.3](#))

SB184 eliminated the requirement to obtain patient signatures, and instead requires that facilities maintain written consent records that contain both of the following:

- A notation that information about informed consent to antipsychotic medications has been discussed with the patient; and
- A notation that the patient understands the nature and effects of antipsychotic medications, and consents to the administration of those medications.

The minimum requirement going forward is to include the above notations within the medical record progress note(s) when prescribing, adding or adjusting antipsychotic or psychotropic medications.

Providers may choose to continue using the Informed Consent for Psychotropic Medications form to document that they have reviewed consent and the nature and effects of antipsychotic or psychotropic medications however, use of this form is not monitored as part of the medical record review and patient signature is not a requirement. A copy of the optional form will remain on the [Optum Website](#) in MHP Provider Documents under the Forms tab.

SB184 does not supersede JV-220 requirements for dependent youth or youth in an out-of-home placement.

For More Information:

- HHSa, QI Matters: qimatters.hhsa@sdcounty.ca.gov